In breast cancer, several cohort analyses report that ERβ (especially ERβ1) expression correlates with more favorable outcomes, supporting a tumor-suppressive role; however, results vary by ERβ isoform, cellular localization, ERα status, and endocrine therapy exposure, with some series noting adverse signals in specific tamoxifen-treated subgroups. The gene discussed is ESR2; the disease is breast carcinoma.